If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M. & 9 othersGrob, J-J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S. & Robert, C., 2018, In : New England Journal of Medicine. 378, 19, p. 1789-1801

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial

Bouman-Wammes, E. W., van den Berg, H. P., de Munck, L., Beeker, A., Smorenburg, C. H., Vervenne, W. L., Coenen, J. L. L. M., Verheul, H. M. W., Gerritsen, W. R. & van den Eertwegh, A. J. M., 2018, In : European Journal of Cancer. 90, p. 1-9

Research output: Contribution to journalArticleAcademicpeer-review

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Westgeest, H. M., Uyl-de Groot, C. A., van Moorselaar, R. J. A., de Wit, R., van den Bergh, A. C. M., Coenen, J. L. L. M., Beerlage, H. P., Hendriks, M. P., Bos, M. M. E. M., van den Berg, P., van de Wouw, A. J., Spermon, R., Boerma, M. O., Geenen, M. M., Tick, L. W., Polee, M. B., Bloemendal, H. J., Cordia, I., Peters, F. P. J., de Vos, A. I. & 3 othersvan den Bosch, J., van den Eertwegh, A. J. M. & Gerritsen, W. R., 1 Sep 2018, In : European Urology Focus. 4, 5, p. 694-701 8 p.

Research output: Contribution to journalArticleAcademicpeer-review